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Abstract
Background
Highly conserved intracellular proteins from Leishmania have been described as antigens in
natural and experimental infected mammals. The present study aimed to evaluate the anti-
genicity and prophylactic properties of the Leishmania infantum Poly (A) binding proteins
(LiPABPs).
Methodology/Principal Findings
Three different members of the LiPABP family have been described. Recombinant tools
based on these proteins were constructed: recombinant proteins and DNA vaccines. The
three recombinant proteins were employed for coating ELISA plates. Sera from human and
canine patients of visceral leishmaniasis and human patients of mucosal leishmaniasis rec-
ognized the three LiPABPs. In addition, the protective efficacy of a DNA vaccine based on
the combination of the three Leishmania PABPs has been tested in a model of progressive
murine leishmaniasis: BALB/c mice infected with Leishmania major. The induction of a Th1-
like response against the LiPABP family by genetic vaccination was able to down-regulate
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the IL-10 predominant responses elicited by parasite LiPABPs after infection in this murine
model. This modulation resulted in a partial protection against L.major infection. LiPABP
vaccinated mice showed a reduction on the pathology that was accompanied by a decrease
in parasite burdens, in antibody titers against Leishmania antigens and in the IL-4 and IL-10
parasite-specific mediated responses in comparison to control mice groups immunized with
saline or with the non-recombinant plasmid.
Conclusion/Significance
The results presented here demonstrate for the first time the prophylactic properties of a
new family of Leishmania antigenic intracellular proteins, the LiPABPs. The redirection of
the immune response elicited against the LiPABP family (from IL-10 towards IFN-γmediat-
ed responses) by genetic vaccination was able to induce a partial protection against the de-
velopment of the disease in a highly susceptible murine model of leishmaniasis.
Author Summary
Leishmaniases are a wide spectrum of parasite diseases caused by the infection of different
species of Leishmania genus in several mammalian hosts, such as humans and dogs,
among others. The induction of antibody responses against some parasite intracellular
proteins implicated in different structural and functional cellular roles has been associated
with parasite survival, infection progression, down-regulation of the cellular immune re-
sponses against the parasites and the development of pathology. The data presented in this
work show the antigenic nature of the three members of the Leishmania infantum Poly
(A) Binding Protein (LiPABP) family in different forms of natural and experimental leish-
maniasis. Using a susceptible model of progressive leishmaniasis (BALB/c mice infected
with Leishmania major), it was shown that the administration of a LiPABPs based com-
bined genetic vaccine was able to induce a partial protection against the disease. Redirec-
tion of the IL-10 mediated responses elicited by the parasite LiPABPs after L.major
infection towards an IFN-γ specific production by vaccination was related to protection.
The inclusion of the LiPABPs in a protective vaccine formulation against leishmaniasis
is discussed.
Introduction
Parasites of the genus Leishmania are protozoan organisms that can infect different mammali-
an species including humans and dogs. Leishmania promastigote forms present in the insect
vectors (phlebotomine sand flies) are transmitted to the vertebrate hosts during the blood meal
[1]. After infection, parasites differentiate in the amastigote forms that multiply inside macro-
phages. The infected vertebrates can present a wide spectrum of clinical manifestations, global-
ly known as leishmaniasis. Depending on the host and the parasite species, the disease can
range from subclinical forms to severe symptomatic leishmaniasis [2]. In humans, there are
various parasite species that cause cutaneous leishmaniasis (CL), including Leishmania major
in the Old World and Leishmania braziliensis in the NewWorld, among other species. CL is
the less severe form of the disease and, in some cases, patients heal spontaneously. A percentage
of the patients infected with L. braziliensis can develop a form of the disease characterized by
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the presence of lesions in mucosal areas, known as mucosal leishmaniasis (ML) [3]. Visceral
leishmaniasis (VL) is the most severe clinical form of the disease and it is presented in human
and canine patients infected with Leishmania infantum (syn. Leishmania chagasi [4]) in the
Mediterranean basin and in South America, or in human patients infected with Leishmania
donovani in Asia and Africa [5]. VL patients usually present hepatosplenomegaly accompanied
by other clinical symptoms like fever, polyclonal hypergammaglobulinemia and anaemia [6].
Infected dogs develop similar systemic symptoms accompanied by cutaneous lesions in the
mucous membranes, skin and eyes [7].
The control of infection in mammalian hosts naturally or experimentally infected with dif-
ferent Leishmania species depends mainly on the induction of cellular responses able to acti-
vate macrophages to eliminate the intracellular pathogens [8]. The induction of CD4+ Th1
cells specific for parasite antigens is critical to control infection due to their ability to secrete
IFN-γ, but the activation of other cell subsets to produce this cytokine, like Leishmania antigen
specific CD8+ T cells, is also required for a protective host response to L.major infection in
the C57BL/6 mice strain. On the contrary, the generation of an IL-4 driven Th2 response after
L.major infection in the susceptible BALB/c mice strain has been related to disease (reviewed
in [9]). In this model of murine leishmaniasis, T cell or B cell derived IL-10 production has also
been implicated in the progression of infection [10,11].
The fact that patients recovered from the disease are resistant to Leishmania reinfection can
be taken as an indication that a vaccine is feasible. Regarding prophylaxis in dogs, there are
three commercial vaccines against canine leishmaniasis: Leishmune, based on the Parasite Fu-
cose-Manose-Ligand [12], Leish-Tec, a vaccine constructed by the recombinant version of the
amastigote specific A2 protein [13] and CaniLeish, composed of promastigote secreted-
excreted factors [14], but none of them are able to completely control the disease [15,16]. In ad-
dition, there is no vaccine against this parasite in humans. Some of the candidates for the devel-
opment of human vaccines have been tested as second generation products (based on parasite
or insect vector saliva defined antigens) or third generation DNA based vaccines in murine ex-
perimental models [17]. The establishment of a protective anti-Leishmania response based on
these recombinant molecules requires the induction of parasite specific long-lasting memory T
cells that will expand as effector T cells for the production of IFN-γ dependent responses
specific for parasite antigens shortly after infection. Some experimental vaccines based on
intracellular proteins that form complexes with nucleic acids, like histones or ribosomal pro-
teins have been related with protection against the disease in different experimental models
[18,19,20,21,22,23].
Poly(A) binding proteins (PABPs) are nuclear or cytosolic factors that contribute to mRNA
metabolism from nuclear polyadenylation and export to translation initiation and control of
RNA turnover in the cytoplasm [24]. PABPs are able to interact with the Poly(A) tail and other
regions of the mRNAs as well as with other protein factors to exert their functions [25]. Three
members of the PABP family have been described in L.major. Two of them, namely LmPABP1
and LmPABP2, are the cytosolic or nuclear (respectively) orthologues of the PABPs from other
kinetoplastids, whereas the third one (LmPABP3) is a nuclear protein only present in the Leish-
mania genus among kinetoplastids [26]. Since the L. infantum PABP2 was recognized by the
sera from VL symptomatic dogs [27] this work has extended the analysis of the antigenicity of
all the members of the LiPABP family. The results of this work have demonstrated the antige-
nicity of the three LiPABPs in human and canine leishmaniasis. In addition, their immunoge-
nicity and protective capacity when administered as a third generation DNA combined vaccine
have been evaluated in a susceptible experimental model of murine leishmaniasis: BALB/c
mice infected with L.major.
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Methods
Mice and parasites
Female BALB/c mice (6–8 weeks old) were purchased from Harlan (Barcelona, Spain). All pro-
cedures were performed according to the Directive 2010/63/UE from the European Union and
RD53/2103 from the Spanish Government and approved by the Animal Care and Use Com-
mittee at the Centro de Biología Molecular Severo Ochoa (reference CEEA-CBMSO 21/138)
and the Bioethical Committee of the Consejo Superior de Investigaciones Científicas (reference
100/2014). The project was finally authorized by the Government of the Autonomous Commu-
nity of Madrid (reference PROEX121/14).
Promastigotes of L. infantum (MCAN/ES/1996/BCN/150/MON-1) and from L.major
clone V1 (MHOM/IL/80/Friedlin) were cultured at 26°C in Schneider medium (Gibco, NY,
U.S.A.) supplemented with 10% Fetal Calf Serum (FCS) (Sigma, MO, U.S.A.), 100 U/ml of pen-
icillin and 100 μg/ml of streptomycin. Parasites were kept in a virulent state by passage in
BALB/c mice. L.major amastigotes were obtained from infected popliteal lymph nodes. After
transformation to the promastigote form, parasites were grown until stationary phase and then
harvested for inoculation in the left hind footpad of mice or for Soluble Leishmania Antigen
(SLA) preparation as described in [22].
Cloning of DNA sequences coding for L. infantum PABPs and
recombinant products manufacturing
The L. infantum PABP1 (LinJ35.V3.5360), PABP2 (LinJ.35.4200) and PABP3 (LinJ.25.0080)
(namely LiPABP1, LiPABP2 and LiPABP3, respectively) coding regions were obtained from
the L. infantum genome database (www.genedb.org) using the L.major orthologous protein se-
quences as probes (LmjF.35.5040, LmjF.35.4130 and LmjF.35.4130) [26]. Coding regions were
PCR amplified using genomic DNA from L. infantum (taking advantage of the lack of intron
sequences in this genus) and the next specific primers: LiPABP1 forward, 5’-CGGGATCCA
TGGACAAGCCGATGCAGATC-3’ and reverse, 5’-CGGATATCACGCCGTCTGATGC
GCCTT-3’; LiPABP2 forward, 50- CGGGATCCATGGCCTTTACTGGTCCGAATC-30
and reverse, 5’-CGGGATCCTCAAACGCTCATGTCTGCCAAG-3’; LiPABP3 (forward,
5’-CGGGATCCATGGTGGTCCCAGTGCAACG-3; reverse, 5’-CGGATATCAGTTGC
CAGTGTGCTGCTGAAG-3’. The restriction sites included for cloning purposes (BamHI for
LiPABP2 and BamHI/EcoRV for LiPABP1 and LiPABP3) are underlined. The resultant PCR
products were inserted into pBluescript II SK (Stratagene. CA, U.S.A). For that purpose the
PCR inserts were purified using the High Pure PCR Product Purification Kit (Roche Diagnos-
tics GmbH, Mannheim, Germany) and the pBluescript II SK and the PCR inserts were digested
with the indicated restriction enzymes (New England Biolabs, MA, U.S.A.) and ligated with the
T4 DNA ligase (New England Biolabs). Positive clones were selected by a restriction analysis
(using the enzymes employed for cloning) and double stranded sequenced. For subcloning
purposes, the three inserts containing the coding regions were obtained by digestion with
BamHI for LiPABP2 and BamHI/EcoRV for LiPABP1 and LiPABP3, and inserted in two dif-
ferent plasmids. For preparing genetic vaccines, the inserts were subcloned in the correspond-
ing sites of the pcDNA3 mammalian expression vector (Invitrogen, CA, U.S.A.). The correct
orientation of the LiPABP2 insert was monitored by a restriction analysis made with ApaI, an
enzyme that cut the LiPABP2 coding region (positions 1651–1656 of a total length of 1756 nu-
cleotides; Gene DB sequence LinJ.35.4200) and it is included in the multiple cloning site of the
pcDNA3 plasmids downstream the BamHI cut site. For vaccination assays, the pcDNA3
vector and the three recombinant pcDNA3 plasmids were purified by the endotoxin-free
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Giga-preparation Kit (Qiagen, Hilden, Germany). Plasmids used in vaccination assays were
suspended in sterile phosphate-buffered saline (PBS). For recombinant protein preparations,
DNA inserts containing the different coding regions were subcloned into the BamHI
(LiPABP2) or the BamHI/SmaI sites (LiPABP1 and LiPABP3) of the pQE30 prokaryotic ex-
pression vector (Qiagen). The correct LiPABP2 insert orientation was examined by restriction
with SmaI enzyme, since the LiPABP2 coding region has a SmaI cut site located at nucleotides
1173–1178 of a total length of 1756 (Gene DB sequence LinJ.35.4200) and it is also located
downstream the BamHI cut sequence in the pQE multiple cloning site. Escherichia coli (M15
strain) transfected with the recombinant plasmids were employed for over-expression of the
his-tagged proteins. For that purpose, E. coli cultures were grown at 37°C in an orbital shaker
to the mid-growth phase (determined by 0.6 value of Optical Density (O.D.) at 600 nm)
and the expression was induced by addition of 1 mM IPTG for 4 h at the same conditions.
Since the three LiPABPs formed inclusion bodies, proteins were solubilized under denaturing
conditions. For ELISA assays, proteins were purified under denaturant conditions onto Ni-
nitrilotriacetic-acid-agarose (Ni-NTA, Qiagen) columns following the manufacturer’s instruc-
tions (The QIAespressionistTM; https://www.qiagen.com/es/resources/resourcedetail?id=
79ca2f7d-42fe-4d62-8676-4cfa948c9435&lang = en). Briefly, proteins were solubilized in bind-
ing buffer (20 mM Tris ClH pH 8.0, 0.5 M NaCl, 8 M Urea, 1 mM β-mercaptoethanol) supple-
mented with 5 mM Imidazole, and mounted into a Ni-NTA gravity flow column. After
washing in the binding buffer supplemented with 20 mM imidazole, proteins were eluted using
the binding buffer supplemented with 0.5 M imidazole. After, purified proteins were dialyzed
against ELISA denaturant coating buffer (20 mM Tris ClH pH 8.0, 0.5 M NaCl, 3 M Urea, 1
mM β-mercaptoethanol). For immunization or cells culture experiments, proteins were purified
under denaturing conditions and refolded on the affinity column as described in [28] adding
20% (p/v) glycerol in those solutions that had not the denaturant agent (urea) to maintain pro-
tein solubility [29]. After purification, proteins were dialyzed against PBS plus 20% (p/v) glycer-
ol. Polymyxin-agarose columns (Sigma) were employed to remove residual endotoxin content
(<10 pg of LPS per μg of recombinant protein, measured by the Quantitative Chromogenic
Limulus Amebocyte Assay QCL-1000 (BioWhittaker, MD, U.S.A.)). Protein concentration was
estimated by Bradford method using the Bio-Rad Protein assay (Bio-Rad, CA, U.S.A.).
Sera and ELISA assays
Human serum samples were obtained from clinical and parasitologically diagnosed patients.
For the present study, anonymized samples were randomly selected from a sera bank
(LIP-CPqGM-FIOCRUZ) built for previous independent studies conducted in Brazil in en-
demic areas for ML [30] or VL [31]. Canine symptomatic VL sera from L. infantum infected
dogs were collected in the Extremadura region of Spain [32]. Control sera were obtained from
healthy individuals (humans or dogs). For ELISA, MaxiSorp plates (Nunc, Roskilde, Denmark)
were coated with 0.2 μg of each one of the recombinant antigens (diluted in ELISA denaturant
coating buffer) for 12 h at 4°C. After four washes with PBS + 0.5% Tween 20 (PBST) wells free
binding sites were blocked with blocking solution (PBST + 5% non-fat milk solution) for 1 h at
room temperature (RT) and incubated with human or canine sera for 2 h at RT (1/200 dilution
in blocking solution). After four washes in PBST, wells were incubated with secondary antibod-
ies conjugated to horseradish peroxidase at 1/2,000 dilution in blocking solution for 1 h at RT
(anti-dog IgG or anti-human IgG from Nordic Immunological Laboratories, Tilburg, The
Netherlands). After four washes in PBST, the reaction was developed through incubation with
orto-phenylenediamine 10 min in the dark, and stopped by addition of 2 N H2SO4. Optical
densities were read at 450 nm in an ELISA microplate spectrophotometer (Bio-Rad).
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From the experimental model, sera were obtained at the beginning of the immunization
(pre-immune sera), four weeks after the last doses (just before challenge with parasites) as well
as seven weeks after challenge with L.major. The procedure for the ELISAs were the same indi-
cated above but the reciprocal end-point titer (defined as the inverse of the highest serum dilu-
tion factor giving an absorbance> 0.15) against the recombinant proteins (0.2 μg per well) or
SLA (1 μg per well) was determined by serial dilution of the sera. Anti-IgG, anti-IgG1 or anti-
IgG2a (all of them at 1/2,000) horseradish peroxidase-conjugated anti-mouse immunoglobu-
lins were used as secondary antibodies (purchased by Nordic Immunological Laboratories).
Expression of LiPABPs in mammalian cells
To confirm that the DNA constructs were functional, COS7 cells were independently trans-
fected with 20 μg of pcDNA3-LiPABP1, pcDNA3-LiPABP2 or pcDNA3-LiPABP3 using the
Fugene reagent (Promega, WI, U.S.A.) according to the manufacturer's protocol. Seventy-two
hours post-transfection, the cells were harvested, washed two times with ice-cold PBS, and im-
mediately lysed by the addition of Laemmli's buffer. The proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellu-
lose membranes (Amersham, Aylesbury, United Kingdom). The blots were probed with mouse
antiserum raised against the LiPABPs (1/200) by the independent immunization of the recom-
binant LiPABPs (three doses, 12 μg of each one) combined with 25 μg of the next two phos-
phorothioate-modified CpG-ODNs: (5’-TCAACGTTGA-3’ and 5’- GCTAGACGTTAGCGT-
3’). Anti-IgG (1/2,000) horseradish peroxidase-conjugated anti-mouse immunoglobulins were
employed as secondary antibodies (Nordic Immunological Laboratories). As control, similar
blots were probed with an anti-human PABP antibody (Cell Signaling, Merck Millipore Darm-
stadt, Germany) and horseradish peroxidase-conjugated anti-mouse immunoglobulins (1/
2,000; Nordic Immunological Laboratories) as secondary reagent. Western blots treated with
anti-LiPABPs sera were revealed with the ECLWestern Blotting System (GE Healthcare
Life Sciences, PA, U.S.A.) and those probed with anti-human PABP were revealed with
4-chloronaphthol (Sigma).
Immunization, parasite challenge and parasite quantification
Three mice groups (n = 16 per group) were made. The LiPABP vaccinated group was inoculat-
ed in the right hind footpad with 200 μg of a mixture of the next recombinant plasmids:
pcDNA3-LiPABP1, pcDNA3-LiPABP2 or pcDNA3-LiPABP3 (66.6 μg of each plasmid). As
control groups, mice were inoculated with PBS or with 200 μg of the pcDNA3 plasmid. Mice
were inoculated three times (two weeks apart). Four weeks after last dose eight mice per group
were euthanized, in order to obtain their spleens to be used in the analysis of the cellular im-
mune responses induced by immunizations. Parasite challenge was carried out at the same
time using the remaining mice by subcutaneous inoculation with 5 × 104 stationary-phase pro-
mastigotes of L.major into their left footpads. For the analysis of the clinical signs of infection,
footpad swelling was measured with a metric caliper (expressed as thickness of the infected left
footpad minus thickness of the right footpad). For parasite load determination, the spleen and
the single popliteal lymph node draining the site of infection (left leg) were collected and inde-
pendently processed. The complete spleens or lymph nodes were mechanically homogenized
in Schneider's medium supplemented with 20% heat-inactivated FCS, 200 U/ml penicillin and
100 μg/ml streptomycin and filtered using a cell strainer (70-μm pore size). Each homogenized
sample tissue was serially diluted (1/3) in a 96-well flat-bottomed microtiter plate containing
the same medium (in triplicates). The number of viable parasites was determined from the
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highest dilution at which promastigotes could be grown up to 10 days of incubation at 26°C as
previously described [33].
Cytokine production
Spleen cells obtained from mice inoculated with saline, with the pcDNA3 vector or with the
LiPABPs combined genetic vaccine were seeded and independently cultured in RPMI complete
medium at 5 × 106 cells per ml (RPMI medium (Sigma)) supplemented with 10% heat-inacti-
vated FCS, 20 mM L-glutamine, 200 U/ml penicillin, 100 μg/ml streptomycin and 50 μg/ml
gentamicin, during 72 h at 37°C in 5% CO2. Mice (n = 8 per group) were euthanized four
weeks after the last dose or seven weeks after parasite challenge. Cells were cultured alone or
with some of the next stimuli: SLA, the recombinant LiPABP1, LiPABP2, LiPABP3 proteins as-
sayed separately (all of them at 12 μg/ml of final concentration), or with a mixture of the three
recombinant LiPABPs at 4 μg/ml each one. The levels of IFN-γ, IL-10 or IL-4 were determined
in the culture supernatants by sandwich ELISA using monoclonal antibodies specific for
mouse cytokines (capture and detection) provided in commercial kits (Pharmingen, San
Diego, CA, USA), following the manufacturer’s instructions.
Statistical analysis
Statistical analysis was performed using the Graph-Pad Prism program. Data were first ana-
lyzed by the D'Agostino & Pearson normality test. Parametric data were analyzed by a two-
tailed Student's t-test and non-parametric data were analyzed by a MannWhitney test.
For both test differences were considered significant when (+) P< 0.05, (++) P< 0.01 or
(+++) P< 0.001.
Results
Antigenicity of the Leishmania PABPs during natural infections
First, the antigenicity of the members of the Leishmania PABP was determined. For this pur-
pose, the three LiPABPs were expressed as recombinant proteins in E. coli, purified by affinity
chromatography and employed for ELISA to investigate the presence of circulating antibodies
against them in the sera from human and canine patients affected by VL. The three LiPABPs
were recognized by Brazilian human patients suffering VL due to the infection of L. chagasi
(syn. L. infantum) (Fig 1A), and by sera samples from Spanish VL symptomatic dogs infected
by L. infantum (Fig 1B). On the basis of the high degree of identity observed between L. infan-
tum and L. braziliensis counterparts (S1 Fig) the cross reactivity between LiPABPs and sera
from patients affected by ML due to L. braziliensis was assayed. The reactivity of the sera from
ML patients was significantly higher than that from healthy donors for the three LiPABPs (Fig
1A). From these data, it was concluded that the three members of the LiPABP family interact
with the host immune system after infection in different vertebrate hosts.
Immunogenicity of LiPABPs administered as a combined DNA-vaccine
To evaluate the immunogenicity of the Leishmania PABPs administered as a combined DNA
vaccine, the coding regions for the LiPABPs (LiPABP1, LiPABP2 and LiPABP3) were individu-
ally cloned into the eukaryotic expression vector pcDNA3. The correct expression of the DNA
vaccines was tested in culture analyzing the expression of the LiPABPs in COS7 cells transfected
with the recombinant plasmids (Fig 2, upper panels). Using sera frommice immunized with the
recombinant versions of the parasite LiPABPs, specific protein bands were observed in the three
immunoblot panels in the lanes corresponding to cell cultures transfected with the recombinant
Leishmania Antigenic PABPs Based Genetic Vaccine
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plasmids (Fig 2, upper panels, lanes 3). No reactivity was observed against proteins from COS7
cell samples un-transfected (Fig 2, upper panels, lanes 1) or transfected with the non-recombi-
nant plasmid (Fig 2, upper panels, lanes 2). The presence of the mammalian PABP was revealed
by probing similar blots with an anti-human PABP antibody (Fig 2, lower panels). The molecu-
lar weights of the parasite LiPABPs expressed by mammalian cells were close to the expected
(hypothetically calculated from their amino acid sequences) and slightly lower to that observed
for the recombinant LiPABPs expressed in bacteria and possessing a histidine tag in the amino-
terminal region (Fig 2, upper panels, lanes 4). The lower bands detected by anti-LiPABPs anti-
bodies may result from cleavage of the proteins expressed in the mammalian cells (Fig 2, upper
panels, lanes 3). Similarly, lower bands observed in the lane 4, upper panel of the Fig 2B, may be
related to partially cleaved forms of the recombinant LiPABP2 protein expressed in E. coli, since
they were absent in protein samples purified under denaturant conditions and appeared when
the denaturant agent was removed by dialysis against PBS (S2 Fig).
Fig 1. The LiPABPs are antigenic in humans and dogs suffering leishmaniasis. Antibody response of
humanML (n = 20) or VL patients (n = 20) and healthy individuals (HC, n = 8) against the three recombinant
LiPABP proteins (A). Antibody responses of canine VL (VL, n = 38) and healthy animal sera (HC, n = 18)
against the recombinant proteins (B). All sera were tested for IgG reactivity by ELISA (1/200). Horseradish
peroxidase-conjugated anti-human IgG (1/2,000) or anti-dog IgG (1/2,000) antibodies were used as the
secondary reagents. Results are shown as whisker (min to max) plots. * (P < 0.05) and *** (P < 0.001)
statistical differences in the IgG reactivity values between each group of patients and their corresponding
healthy control sera group, evaluated by the Mann-Whitney test.
doi:10.1371/journal.pntd.0003751.g001
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Once determined the correct expression of the three Leishmania PABPs, plasmid DNAs
were administered to mice as a mixed formulation (combined genetic vaccine). The cellular
and humoral responses elicited by the LiPABP combined genetic vaccine were compared to
those observed in two control mice groups: one receiving the vaccine saline diluent (PBS) and
one receiving the pcDNA3 plasmid (as an adjuvant control). Mice vaccinated with the LiPABP
genetic combined vaccine showed a positive IgG response against parasite proteins that was ab-
sent in both control groups. An IgG2a versus IgG1 dominant antibody response was observed
in vaccinated mice against the antigens composing the vaccine when they were assayed by
ELISA, together or separately (Fig 3A). The LiPABP1 protein was the most immunogenic of
the three tested LiPABPs in BALB/c mice. No reactivity against SLA was observed in the sera
of control or vaccinated mice. The systemic cellular response elicited by the immunizations
was studied by the in vitro stimulation of spleen cells cultures established from control and
LiPABP vaccinated BALB/c mice. A parasite LiPABP-specific secretion of IFN-γ and IL-10 was
observed in mice vaccinated with the LiPABP based genetic vaccine. IFN-γ was the most abun-
dant cytokine detected in cultures supernatants after stimulation of cells with each one of the
LiPABPs or with a mixture of the three proteins (Fig 3B). Low levels of IL-4 were detected in all
cell cultures supernatants assayed. Since the assays were performed in the absence of an IL-4
receptor blocking antibody it cannot be discarded the consumption of the cytokine in superna-
tants of cells stimulated with the antigens [34]. However, the low titer of LiPABPs specific IgG1
antibodies found in the LiPABP vaccinated mice (an IL-4-dependent isotype [35]) is reflecting
the generation of poor Th2 responses. From both humoral and cellular data, it was concluded
that the mixed genetic vaccine induced a predominant Th1-biased immune response specific
for the three members of the LiPABP family.
Fig 2. Analysis of the expression of the L. infantum genes coding for the three LiPABPs in mammalian cells. SDS-PAGE in which 10 μg of total
proteins obtained from a COS cell culture (lane 1), COS cell transiently transfected with the pcDNA3 eukaryotic expression vector (lane 2) or cell lines
transfected with DNA plasmids pcDNA3-LiPABP1 (A), pcDNA3-LiPABP2 (B) or pcDNA3-LiPABP3 (C) (lanes 3) were resolved. Two μg of the corresponding
recombinant proteins expressed in Escherichia coli were resolved in the lane 4 of the different gels. After blotting, the expression of the three proteins in the
transfected cultures protein was monitored by the detection of the parasite LiPABPs using specific antiserum against LiPABPs obtained frommice
immunized with the corresponding recombinant proteins (1/200) (Upper panels). Horseradish peroxidase-conjugated anti-mouse IgG antibodies (1/1,000)
were employed as the secondary reagent. ChemiluminescenceWestern blot detection of each panel is shown. Similar blots were incubated with an anti-
human antibody (1/2,000) to reveal the presence of the mammalian PABP (lower panels). In this case, horseradish peroxidase-conjugated anti-rabbit IgG
antibodies (1/2,000) were used. Blots revealed with 4-cloronaphtol are shown.
doi:10.1371/journal.pntd.0003751.g002
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Vaccination of mice with the genetic LiPABP-based combined vaccine
protects BALB/c mice against L.major challenge
Since the induction of a Th1 response against different parasite antigens has been related with
protection in experimental models of CL we next analyzed whether the immunization with the
Fig 3. The immunization of the LiPABP genetic combined vaccine induces a predominant Th1-biased response against the LiPABP family in
BALB/c mice.Mice (n = 16 per group) were immunized three times with phosphate saline buffer (saline), with the pcDNA3 plasmid or with the LiPABP1
+ LiPABP2 + LiPABP3 combined genetic vaccine. The presence of anti—LiPABP1, anti-LiPABP2, anti-LiPABP3 and anti-LiPABPs IgG1 and IgG2a
immunoglobulins were individually determined four weeks after the last doses. Sera were assayed from 1/100 to 1/820,000 and horseradish peroxidase-
conjugated anti-mouse IgG1 or IgG2a were used as the secondary antibodies at 1/2,000 (A). Results are shown as whisker (min to max) plots. * (P < 0.05)
and ** (P < 0.01) statistical differences between IgG1 and IgG2a reactivity values evaluated by the Mann-Whitney test. At the same time spleen cell cultures
were established from eight mice. Splenocytes (5 x 106 cells/ml) were cultured for 72 h at 37°C, 5% CO2 in the presence of parasite LiPABP1, LiPABP2 and
LiPABP3 as independent stimuli (12 μg/ml) or a mixture of the three proteins (12 μg/ml total protein, 4 μg/ml each one). As background control, parallel
cultures were maintained without stimulation (Medium). The levels of IFN-γ, IL-10 and IL-4 were determined by capture ELISA in culture supernatants (B).
Each bar represents the mean ± standard deviation (SD) of data taken from eight individual mice. + P < 0.05, ++ P < 0.01 and +++ P < 0.001 significant
differences between LiPABP vaccinated and saline control mice; ** P < 0.01 and *** P < 0.001 significant differences between LiPABP vaccinated mice and
pcDNA3 immunized control mice (Student T-test). Results are representative of two independent experiments.
doi:10.1371/journal.pntd.0003751.g003
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combined vaccine was able to induce protection against L.major infection in the highly suscep-
tible BALB/c strain. For that purpose, mice vaccinated with the LiPABP based genetic vaccine
as well as mice from control groups (inoculated with the non-recombinant plasmid or the sa-
line diluent of the vaccine) were infected with L.major, one month after the last immunization.
Mice vaccinated with the LiPABP combined vaccine showed lower footpad swelling than con-
trol groups inoculated with the vaccine diluent or the non-recombinant plasmid, from week 3
after challenge to the end of the assay (Fig 4A). The time for euthanization, seven weeks post-
infection, was determined by the appearance of necrotic lesions in control groups that were ab-
sent in the LiPABP vaccinated group. In addition, LiPABP vaccinated mice showed a 1.25-log
and 1.21-log reduction in the parasite burdens of the lymph node draining the infected footpad
(popliteal lymph node) relative to saline and pcDNA3 immunized control groups, respectively
(Fig 4B). Similarly, it was determined the existence of a 1.5-log and 1.4-log reduction in the
number of viable parasite detected in the spleen of LiPABP vaccinated mice relative to both
control groups (Fig 4B).
Since the level of the humoral responses elicited against leishmanial antigens in mice in-
fected with L.major has been correlated to the severity of the disease [36] the humoral response
against SLA was analyzed in the three mice groups assayed. At week seven after infection the
titer of SLA-specific IgG antibodies in the LiPABP vaccinated mice group was lower than the
titer observed in the non-protected control groups (Fig 5A). In addition, the polarization to-
wards a Th2 response demonstrated by titers of SLA-specific IgG1 antibodies observed in both
control groups is absent in the LiPABP vaccinated group (Fig 5B). The cellular response against
SLA was then analyzed using spleen cells cultures established from mice from the three tested
groups. A significant decrease in the production of SLA-induced IL-10 and IL-4 was observed
in the LiPABP vaccinated and protected mice, relative to both control groups (Fig 5C). Even
though similar levels of IFN-γ were found in the supernatants of cultures after stimulation with
SLA the ratio of IFN-γ/IL-10 and IFN-γ/IL-4 was significantly higher in the protected mice
group than in animals from both control groups (Fig 5D). As control, spleen primary cultures
were grown in the same conditions but in the absence of any other stimuli. The cytokine
levels found in these supernatants were very low (Fig 5C; Medium). Therefore, the parasites
colonizing the spleen of infected mice were not contributing to cytokine release in the in vitro
stimulation assay.
It was concluded that immunization with the LiPABPs combined vaccine induced a delay in
the progression of CL due to L.major infection. This partial protection was correlated to the
decrease of parasite specific IL-4 and IL-10 mediated responses, in the absence of changes in
the magnitude of the parasite dependent IFN-γ production.
Administration of the genetic combined vaccine was able to switch the
immune response elicited against the LiPABP family after infection
The immune response against the LiPABPs after challenge was studied in mice vaccinated with
the LiPABP genetic vaccine as well as in mice without a previous contact with these antigens,
namely saline and pcDNA3 to analyze how infection affects the immune response elicited
against the proteins composing the LiPABP vaccine in immunized mice, but also in animals
without a previous contact with these proteins (saline and pcDNA3 groups).
Regarding the humoral response, high IgG1 and IgG2a antibody titers were observed in the
sera from LiPABP vaccinated animals after infection (Fig 6A). The predominant IgG2a re-
sponse against the LiPABP family induced by vaccination was maintained after parasite chal-
lenge in this mice group (Fig 6A). The LiPABP1 (Fig 6B) was the most antigenic member of
the family followed by LiPABP2 (Fig 6C), being LiPABP3 the lesser antigenic member of the
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Fig 4. Course of L.major infection in BALB/c mice vaccinated with the LiPABP DNA combined
vaccine.Mice (n = 8 per group) vaccinated with the LiPABP1 + LiPABP2 + LiPABP3 combined genetic
vaccine (pcDNA3-PABPs) or inoculated with the pcDNA3 empty vector (pcDNA) or receiving the vaccine
diluent (Saline) were challenged in the footpad with 5 × 104 L.major stationary promastigotes one month after
the last immunization. Footpad swelling is represented as the mean ± SD of the difference of thickness
between the infected and the uninfected contra-lateral footpads (A). The numbers of viable parasites in the
popliteal lymph nodes draining the infected legs (DLN) or in spleens were individually determined by limiting
dilution at week seven post-challenge. Mean ± SD of the parasite burdens in the complete organ is shown
(B). + P < 0.05, ++ P < 0.01 and +++ P < 0.001 significant differences between LiPABP vaccinated and saline
control mice; * P < 0.05, ** P < 0.01 and *** P < 0.001 significant differences between LiPABP vaccinated
mice and pcDNA3 immunized control mice (Student T-test). Results in each panel are representative of two
independent experiments.
doi:10.1371/journal.pntd.0003751.g004
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family (Fig 6D). On the contrary, control groups showed a limited humoral response against
the LiPABPs antigens, being the IgG1 titers higher than the IgG2a ones (Fig 6A–6D). Signifi-
cant differences between both subclasses were only observed in both control groups when a
mix of the three proteins were employed for coating ELISA plates (Fig 6A) or in the saline
group for Leishmania LiPABP1 (Fig 6B).
Fig 5. Antibody titers and cytokines production against SLA after infection in control and vaccinated mice groups. The humoral and cellular
response against soluble Leishmania antigens (SLA) was determined at week seven after L.major infection in mice (n = 8 per group) previously vaccinated
with the LiPABP1 + LiPABP2 + LiPABP3 combined genetic vaccine (pcDNA3-PABPs) or immunized with the pcDNA3 empty vector (pcDNA) or that received
the vaccine diluent (Saline) prior to infection. Anti—SLA IgG (A) or IgG1 and IgG2a (B) titers were individually determined by assaying sera from 1/50 to 1/
820,000 and using a horseradish peroxidase-conjugated anti-mouse IgG, IgG1 or IgG2a secondary antibody at 1/2,000 dilution. Results are shown as
whisker (min to max) plots. For cytokine determinations spleen cells were cultured for 72 h at 37°C, 5% CO2 in the absence or in the presence or soluble
Leishmania antigen (SLA; 12 μg/ml). Levels of IFN-γ, IL-10 and IL-4 were assessed by ELISA in culture supernatants (C). Each bar represents the
mean ± standard deviation (SD). The IFN-γ/IL-10 and IFN-γ/IL-4 ratios were determined and represented as the mean ± standard deviation (SD) (D). In (A)
++ (P < 0.01) and ** (P < 0.01) statistical decrease in anti-SLA response in the LiPABPs vaccinated group with respect saline or pcDNA3 control groups,
respectively. In (B) ** (P < 0.01) and *** (P < 0.001) statistical differences between IgG1 and IgG2a anti-SLA titers within each group (Mann-Whitney test).
In (C and D) +++ P < 0.001 and *** P < 0.001 significant differences between LiPABP vaccinated and saline and pcDNA3 control groups, respectively
(Student T-test). Results are representative of two independent experiments.
doi:10.1371/journal.pntd.0003751.g005
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The cellular response induced against the LiPABPs by infection was also analyzed in the
three mice groups after challenge. An IFN-γmediated response was only observed in the ani-
mals immunized with the LiPABP genetic combined vaccine (Fig 7A). Similar levels of IL-4 and
IL-10 specific for LiPABPs were observed in all mice groups (Fig 7A). Very low levels of IL-4
were observed in supernatants of cultures stimulated with the recombinant LiPABPs; less than
20 pg/ml for all groups and antigens tested. Consumption of the cytokine in supernatants of
cells stimulated with the antigens can-not be discarded, since the assays were performed in the
absence of an IL-4 receptor blocking antibody. A robust IL-10 mediated response was observed
against the LiPABPs proteins. At week seven after infection, the three proteins were able to in-
duce the secretion of IL-10 in the spleen cells cultures established frommice belonging to both
control groups (Fig 7A). The higher values of the IL-10/ IFN-γ ratio obtained in control groups
(Fig 7B) suggest that the members of the LiPABP family may be acting as an anti-inflammatory
Fig 6. Analysis of the humoral response induced against the LiPABPs after challenge. IgG1 and IgG2a antibody titers specific for a mix of the LiPABPs
(A; Mix), LiPABP1 (B), LiPABP2 (C) and LiPABP3 (D) were individually determined by ELISA in mice (n = 8) immunized with a mixture of pcDNA3 plasmids
encoding the LiPABP1, LiPABP2 and LiPABP3 proteins (pcDNA-LiPABPs), or controls groups inoculated with saline (Saline) or immunized with pcDNA3
vector (pcDNA) and challenged with L.major one month after last immunization. Prior to titer determination, sera were assayed at 1/200 dilution to monitor
the reactivity against the LiPABP proteins. For sera showing moderate reactivity titers were determined from 1/50 to 1/12,8000. For sera showing high
reactivity, titers were determined from 1/500 to 1/1,024,000. Horseradish peroxidase-conjugated anti-mouse IgG1 or IgG2a were used as the secondary
antibodies at 1/2,000. Results are shown as whisker (min to max) plots. * (P < 0.05) and ** (P < 0.01) statistical differences between IgG1 and IgG2a
reactivity values evaluated by the Mann-Whitney test. Results of each panel are representative of two independent experiments.
doi:10.1371/journal.pntd.0003751.g006
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Fig 7. Cytokine production against the LiPABPs after infection in control and vaccinated mice groups. Spleen cell cultures frommice that received
saline (Saline), or that were immunized with pcDNA3 plasmid (pcDNA) or with the LiPABP1 + LiPABP2 + LiPABP3 combined genetic vaccine
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stimulus during infection. The lower value of the IL-10/ IFN-γ ratio observed in the LiPABP
vaccinated and protected mice after infection indicates that the Th1 response induced by vacci-
nation with the genetic combined vaccine against the three member of the LiPABP family was
maintained after infection (Fig 7B). Very low levels of the different cytokines were found in cul-
tures grown without stimulation (Fig 7A; Medium).
Discussion
Human and canine VL patients present high titers of antibodies against different parasite anti-
gens. Many of them are proteins with an intracellular location (like cytosolic or nuclear factors)
having a physiological role inside the cell. These antigenic molecules have been named pananti-
gens, because of their conserved nature and their antigenicity in different forms of leishmaniasis
as well as in other autoimmune or infectious diseases [37,38]. Alternatively, they are termed
pathoantigens [39], because the antibodies produced against them during infection seem to be
involved in the development of pathology in the visceral forms of the disease [36,40]. Data
shown in this work indicate that the LiPABP family can be included within these groups. They
are antigenic in human and canine VL patients and they have an intracellular location [26]. As
occur for other pathoantigenic proteins, LiPABPs have essential roles in the parasite, controlling
the RNA processing and translation [26]. Beside the LiPABPs, other RNA binding proteins, like
the Leishmania PUF family of protein factors have been described as antigenic in natural and
experimental VL [41]. Interestingly, other intracellular ribonucleoprotein complexes (like ribo-
somes or nucleosome forming histones) or components of protein aggregates (like heat shock
proteins) were classified within the panantigenic/pathoantigenic family [37,38,39]. The
LiPABPs are also recognized by the sera from patients with other clinical manifestations, namely
ML human patients infected by L. braziliensis (Fig 1), as occur with other intracellular parasite
proteins families. The presence of antibodies against intracellular proteins in sera samples from
patients of CL an ML, as well as in cured VL patients, reflects the strong antigenicity of these
families [30,31,42]. Some variability in the recognition of the individual LiPABPs was observed
among sera samples from different patients. This is a hallmark of the humoral response found
in human or canine patients for most of the characterized Leishmania antigenic proteins
[43,44]. This variability should be taken into account in the development of vaccines or diagnos-
tics for human and canine leishmaniasis. Regarding the specificity of the humoral response elic-
ited against LiPABPs, in a previous report it was shown that anti-LiPABP2 antibodies purified
from VL canine sera did not show cross-reactivity with the human PABP [27]. The molecular
basis of the response specificity might be related to the high degree of divergence between
LiPABPs and their human orthologues (S3 Fig). In addition, as it is deduced from Fig 2, anti-
bodies elicited against the three LiPABPs in mice immunized with the recombinant versions of
the three LiPABPs were not able to recognize the mammalian PABP.
The induction of humoral responses against these proteins in natural leishmaniasis may de-
pend on specific recognition by the B-cell receptor following parasite destruction after lysis of
the parasites mediated by the complement [45,46] or through the activity of NETs (Neutrophil
Extracellular Traps) [47,48]. The identification of many of the pathoantigenic proteins in the
(pcDNA-LiPABPs) were established at week seven after challenge with L.major (n = 8 per group). Splenocytes (5 x 106 cells/ml) were cultured for 72 h at
37°C, 5% CO2 in the presence or parasite LiPABP1, LiPABP2 and LiPABP3 as independent stimuli (12 μg/ml), or with a mixture of the three proteins (12 μg/
ml total protein, 4 μg/ml each one). As background control, parallel cultures were maintained without stimulation (Medium). Levels of IFN-γ, IL-10 and IL-4
were assessed by ELISA in culture supernatants. Each bar represents the mean ± standard deviation (SD) (A). The IL-10/ IFN-γ ratio from data shown in
panel A was calculated and represented as the mean ± standard deviation (SD) (B). + P < 0.05, ++ P < 0.01, +++ P < 0.001 or; * P < 0.05, ** P < 0.01,
***P < 0.001 significant differences between LiPABP vaccinated and saline or pcDNA3 control mice groups, respectively (Student T-test). Results are
representative of two independent experiments.
doi:10.1371/journal.pntd.0003751.g007
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secretome/excretome of Leishmania species [49,50] offers an alternative manner of presenta-
tion of these antigens to the host immunological system. In this sense, LiPABP2 has been
found to be part of the secretome of L. donovani [50]. As the infection progresses, the release of
the pathoantigens will increase due to the increment in the parasite burden with a concomitant
induction of humoral responses that correlate with the development of the immunopathology
associated with the progressive forms of leishmaniasis [38,39]. An association between the de-
velopment of clinical symptoms and the induction of humoral responses was reported in longi-
tudinal studies developed in different experimental models of VL in dog and hamster [51,52].
Some of these intracellular proteins have immunological properties able to modulate the type
of response against the parasite. As examples, the cytosolic tryparedoxin, a protein that targets
B cells to secrete IL-10 and to produce anti-tryparedoxin specific antibodies [53] or the ribosom-
al protein S3a that induces polyclonal expansion of B cells in the host [54]. Additionally, some
nuclear factors like the protein termed Le22 or the histone H2B specifically activate IL-10 secre-
tion in peripheral blood mononuclear cells (PBMCs) from human VL patients [55,56]. In this
sense, our results indicate that BALB/c mice infected with L.major elicited a moderate humoral
response (IgG1 polarized) against the three Leishmania PABPs (Fig 6). In spite of the low titer
found against the LiPABP in mice from control groups (Fig 6), our data allow to determine that
LiPABP proteins are antigenic in mice infected with L.major. Supporting this conclusion, a
comparative analysis of data shown in Fig 3 and data shown in Fig 6 demonstrate that infection
was able to boost the humoral response elicited against the LiPABP family in mice vaccinated
with the LiPABP combined genetic vaccine. In addition, the high value of the IL-10/ IFN-γ ratio
observed in mice from control groups after infection when the LiPABPs were employed to stim-
ulate spleen cell cultures (Fig 7) reinforces the pathoantigenic characteristics of these protein
factors, since IL-10 mediated responses promote susceptibility in this mice model [11,57].
It has been proposed that down-modulation of IL-10 mediated responses or the Th2-
primed antibody production against pathoantigens can be a promising strategy for the devel-
opment of vaccines [21,55,58]. Supporting this hypothesis, some pathoantigenic molecules like
histones H2A and H2B (antigenic nuclear factors recognized by the sera from human VL pa-
tients [59] or dogs infected by L. infantum [60]) have also been implicated in the induction of
proliferative responses and IFN-γ production in PBMCs from cured CL patients and from
asymptomatic VL patients [61]. In addition, histone H2B has been described to stimulate IFN-
γ producing CD4+ T from donors who developed a protective immune response against Leish-
mania [62]. The immunization of vaccines based on the pathoantigenic histones has been asso-
ciated with the induction of protection in the BALB/c-L.majormodel when Th1 inducing
adjuvants or strategies were employed [22,63]. Other well-known example is the protein
termed LACK; leishmanial homolog of mammalian receptor for activated C kinase. Although
LACK was characterized as an antigen recognized by a protective CD4+ T cell clone (Th1) ob-
tained from a BALB/c mice immunized with a SLA fraction [64], it was later found to be impli-
cated in the induction of the early IL-4 response against L.major occurring in this susceptible
model [65]. Remarkably, co-administration of recombinant LACK with Th1 adjuvants in
BALB/c mice was able to redirect the naturally induced Th2 responses after L.major infection.
Thus, recombinant LACK protein administered with interleukin-12 [66] or as a LACK based
DNA vaccine [67] protected BALB/c mice against L.major infection. Further, it was demon-
strated that BALB/c rendered tolerant to LACK, as a result of transgenic expression of this mol-
ecule in the thymus, were resistant to infection with L.major and developed a Th1 response
after infection [68]. Finally, the use of a intranasal LACK DNA vaccine was able to induce a
protective immunity in BALB/c against the infection by L. amazonensis [69] a NewWorld dis-
tributed species able to cause a broad spectrum of clinical manifestations, from cutaneous to
visceral leishmaniasis in human patients [70].
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Our results show that the inoculation of a genetic vaccine based on the three LiPABP pro-
teins was able to delay the progression of the disease caused by L.major infection in BALB/c
mice by decreasing the footpad swelling and the parasite burdens from LiPABP vaccinated
mice relative to control mice group (Fig 4). This experimental model has been employed be-
cause it is highly susceptible to infection showing a progressive form of the disease, as occurs in
different clinical forms of leishmaniasis in natural hosts [71]. In addition to these clinical or
parasitological evidences, LiPABP vaccinated mice showed a limited humoral response against
SLA as well as high SLA-dependent ratios of IFN-γ/IL-4 and IFN-γ/IL-10 (Fig 5) that can be
considered immunological markers of protection [11,72,73]. The strategy of employing
LiPABP eukaryotic expression plasmids for inoculation was selected due to the capacity of
these third generation vaccines to promote a Th1 response against the heterologous Leishman-
ia proteins expressed in the hosts [74]. Due to the heterogenicity of the immune response elic-
ited against LiPABPs in natural and experimental hosts, we used a combined genetic vaccine,
instead of the immunization of plasmids encoding the individual antigens. It is likely that the
three LiPABPs may be presented to the immune system at the same time after parasite lysis
(for B-cell responses) or presented at the same time by professional antigen presenting cells.
Thus, induction of a Th1 response against the three proteins may help to reinforce the capacity
of the vaccine in controlling disease progression. Using the same mice model employed in this
work, the protective capacity of a vaccine based on histones was reinforced when it was formu-
lated including the four nucleosome histones instead of the use of vaccines based on individual
or different pairs of histones [75]. It has been generally demonstrated that experimental vac-
cines combining different parasite antigens conferred more solid protection than those con-
taining individual parasite determinants (reviewed in [17,74]). Our results demonstrated that
genetic vaccination of the LiPABPs combined vaccine in BALB/c mice induced a Th1 type re-
sponse: anti-LiPABP IgG2a antibodies and IFN-γ secretion upon re-stimulation of spleen cells
with the recombinant LiPABPs (Fig 3). The immune response induced by LiPABP vaccination
was maintained after infection. The PABPs specific IgG2a/IgG1 and IFN-γ IL-10 ratios were
reverted in the LiPABP vaccinated and protected mice, in comparison to mice from both con-
trol groups after infection (Figs 6 and 7). Even though SLA is a preparation of total parasite sol-
uble proteins, including the LiPABPs, opposite patterns in SLA specific (Fig 5B) and LiPABPs
specific (Fig 6) antibody responses were observed when sera from LiPABP vaccinated and in-
fected mice were employed. These differences may be related to the amounts of the LiPABPs
present in the SLA preparation. Thus, ELISA assays performed with the whole antigenic reper-
toire of the parasite may minimize the reactivity of the anti-LiPABPs antibodies. In this con-
text, the anti-SLA immune response can be considered a marker of the immune humoral
response against the whole parasite.
Despite the partial protection afforded by the LiPABP combined vaccine in the BALB/
c-L.majormodel, the use of these proteins as protective antigens should not be underestimated.
Some vaccine candidates inducing partial protection in this mice model have emerged as good
candidates when tested in other models of infection. As an example BALB/c mice immunized
with a DNA vaccine based on L. infantum P0 (LiP0) or with the recombinant LiP0 protein com-
bined with a Th1 inducing adjuvant, presented a partial protection after challenge with L.major
[76,77]. LiP0 vaccinated mice showed an initial significant reduction in lesion size after chal-
lenge, but mice ultimately developed non-healing lesion. The delay in the onset of cell growth
was accompanied by a substantial decrease in the parasite load and was correlated to the genera-
tion of initial Th1 responses that were changed to a mixed Th1/Th2 response against the LiP0
when disease progressed. Interestingly, our data showed that the immune response induced by
vaccination against the LiPABP family members was not changed after infection. On the other
hand, the Th1 responses induced by administration of the LiP0 vaccines conferred protection
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against CL in C57BL/6 mice [77] or against VL in hamster [78]. Similarly, vaccines based on the
L.major ribosomal protein LmL3 or LmL5 combined with CpG-ODNs in BALB/c mice induced
partial protection against CL due to L.major or L. amazonensis but protect mice against VL
caused by L. infantum and against murine CL due to a high virulent challenge of L. braziliensis
[19,44]. Remarkably, some other vaccines described as protective in the L.major-BALB/c model
were unable to induce protection in the later model [79]. Data presented here should be taken as
a proof of concept regarding the protective characteristics of Leishmania PABPs and further as-
says using alternative forms of administration and different models of experimental infection
should be performed to determine the real potential of the PABPs for the development of vac-
cines. As an example, DNA vaccines based on the LACK antigen were able to induce robust
Th1 responses but were unable to protect mice from L.mexicana [80], L. donovani [81] or
L. chagasi [82] infection. Notwithstanding, it was demonstrated that the induction of more com-
plex immune responses, using prime boost strategy, combining a DNA vaccine and attenuated
viruses (Western reserve virus or vaccinia virus) expressing LACK was correlated to protection
against murine VL caused by L. infantum infection [83]. In this sense, dogs experimentally in-
fected with L. infantum were protected against VL following an heterologous prime-boost vacci-
nation regime with a DNA vaccine encoding LACK and recombinant vaccinia virus (rVACV)
expressing LACK [84], or its corresponding non-replicative modified vaccinia (MVA-LACK)
[85]. In addition, combination of LiPABPs with other protective antigens should not be ruled
out. Of interest, this work demonstrate that Leishmania PABPs are antigenic in different verte-
brate hosts infected by distinct parasite species (L. infantum and L. braziliensis in human, L. in-
fantum in dogs and L.major in mice) and the high degree of Leishmania PABPs sequence
conservation in different Leishmania species (S1 Fig) makes plausible to test their cross-protec-
tive properties. The possibility to induce cross-protection by the use of vaccines based in pro-
teins conserved among Leishmania species is one of the advantages of this type of vaccines [86].
As conclusion, this work has established for the first time the antigenicity of the LiPABPs in
different forms of natural leishmaniasis, as well as in BALB/c mice infected with L.major. In this
model of murine progressive leishmaniasis, the administration of a LiPABPs based vaccine was
able to dampen the LiPABP-specific humoral and IL-10 mediated responses detected in the
non-vaccinated mice after infection. This control of pathogenic-skewed immune responses cor-
related to the induction of partial protection. In accordance with previous reports, data presented
here indicate that controlling the responses associated with susceptibility and elicited by parasite
pathoantigens may be relevant to achieve a protective vaccine against Leishmania infection.
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